SCHEMBL474743

SCHEMBL474743

COC(=O)c1ccc2c(c1)OCC(=O)N2C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
POLB P06746 1/20 0.53
CASP3 P42574 2/20 0.51
CYP11B2 P19099 2/20 0.47
CYP11B1 P15538 1/20 0.47
HTR1A P08908 2/20 0.43
HTR2C P28335 1/20 0.43
KDM4E B2RXH2 3/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 2/20 0.42
ALOX15 P16050 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PTGER3 P43115 1/20 0.41
SENP7 Q9BQF6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30040938 1.00 SMN1; SMN2 (0.53) SMN1; SMN2POLBCASP3CYP11B2CYP11B1
SCHEMBL3213901 0.89 SMN1; SMN2 (0.56) SMN1; SMN2POLBCASP3CYP11B2CYP11B1
SCHEMBL8146771 0.84 CYP11B2 (0.50) CYP11B2CYP11B1HTR1AHTR2CKDM4E
SCHEMBL21818855 0.84 CYP11B2 (0.50) CYP11B2CYP11B1HTR1AHTR2CPDE3B
SCHEMBL8039859 0.83 ALDH1A1 (0.46) SMN1; SMN2POLBCASP3ALDH1A1HSD17B10
SCHEMBL18031263 0.83 ALDH1A1 (0.46) SMN1; SMN2POLBCASP3ALDH1A1HSD17B10
SCHEMBL8039033 0.83 ALDH1A1 (0.47) SMN1; SMN2POLBCASP3ALDH1A1
SCHEMBL8039853 0.83 SMN1; SMN2 (0.44) SMN1; SMN2POLBCASP3KDM4ENPC1
SCHEMBL23768991 0.81 NPC1 (0.49) SMN1; SMN2POLBCASP3KDM4ENPC1
SCHEMBL31490337 0.81 NPC1 (0.49) SMN1; SMN2POLBCASP3KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY 2023-01-26 US disclosed
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY 2023-01-26 US disclosed
CN-115427035-A ENL/AF9YEATS inhibitors 洛克菲勒大学 2022-12-02 CN disclosed
WO-2021127166-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY (US) 2021-06-24 WO disclosed
WO-2021127166-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY (US) 2021-06-24 WO disclosed
EP-2411365-B1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-03-19 EP disclosed
US-20130172335-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2013-07-04 US disclosed
US-8450313-B2 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds HOFFMANN-LA ROCHE INC. (US) 2013-05-28 US disclosed
US-8268820-B2 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-09-18 US disclosed
US-20120232071-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HUNZIKER DANIEL (CH) 2012-09-13 US disclosed
EP-2411365-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-02-01 EP disclosed
WO-2010108903-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed
US-20100249124-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172335-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, MC2R SMN1; SMN2 4796/4885POLB 3172/4885CASP3 4087/4885
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS MLLT3, YEATS2, MLLT1 SMN1; SMN2 4608/4885POLB 4736/4885CASP3 1132/4885
US-20100249124-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, MC2R SMN1; SMN2 4789/4885POLB 3091/4885CASP3 4053/4885
US-20120232071-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, MC2R SMN1; SMN2 4796/4885POLB 3172/4885CASP3 4087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.